Home › Trial NCT04684108
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Trial IDNCT04684108
- StatusActive Not Recruiting
- PhasePhase 1
- Study typeInterventional
- SponsorHangzhou Sumgen Biotech Co., Ltd.
- Enrollment61
- Start date2021-11-04
- ConditionsRelapsed or Refractory Multiple Myeloma · Hematological Malignancy
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.